



CERTIFICATE NO.	LAB SAMPLE ID	ISSUE DATE	REPORT STATUS
COA-2026-26260	20260900490	18 Oct 2026	FINAL

01 CLIENT & PRODUCT INFORMATION

Client organization	Redline Bio Labs	Client contact	redlinebiolabs@yahoo.com
Product name	BPC-157/TB-500	Client lot / batch	BB-001
Label claim	10 mg/vial	Lab sample ID	20260900490
Sample matrix	Lyophilized	Quantity received	1
Container / closure	Clear vial/white cap	Condition on receipt	Intact
Date received	09 Oct 2026	Testing period	10-16 Oct 2026
Storage condition	Ambient	Route / intended use	RUO

02 ANALYTICAL TEST RESULTS | Purity, identification and net content

Analysis	Method / SOP	Instrumentation	Result	Units	Acceptance criterion	Status
Purity	UPLC-UV	Acquity UPLC/PDA	99.76	% area	>99%	PASS
Identification	UPLC-MS	Waters Quattro Series	Conforms	—	Ionization profile match w/standard	PASS
Net content	Quantitative UPLC	Acquity UPLC/PDA	TB-4 full-chain: 5.08 BPC-157: 5.28 Total: 10.36	mg/vial	±10% of total label claim	PASS

03 SUPPORTING ANALYTICAL EVIDENCE




PRODUCT AS RECEIVED

BPC-157/TB-500 10 mg Batch BB-001

20260900490B Sm (Mn, 2x3)


(1) PDA Ch1 214nm@4.8nm
Range: 6e-1
Area



BPC-157/TB-500 10 mg Batch BB-001

20260900490B 274 (5.064) Sm (Mn, 2x0.75); Cm (268:303)

Scan ES+
5.72e6





04 AUTHORIZATION | Review, decision rule and release

Analyst	Jason Snitker	Technical reviewer	Vanessa Montoya, PhD
Authorized signatory	Jason Snitker	Decision rule	Document complete, fields correct, analysis reviewed
Deviations / qualifiers	The TB-500 component is reported as TB-4 full-chain. Net content acceptance applies to total content.	Amendment history	N/A

Report conditions: Results are analytical findings for the item tested and do not constitute an endorsement of product safety, efficacy or regulatory status. Unless otherwise stated, this certificate may be reproduced only in full with written approval from AV Analytics.